|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
A Historical Perspective on Radioligand Therapy and Novel Treatment Modalities in the Management of mCRPC
|
Neil H. Bander, MD
Neil Bander joins Charles Ryan providing a historical perspective on radioligand therapy and the history of prostate-specific membrane antigen for prostate cancer treatment.
|
|
|
|
|
|
|
|
|
|
|
|
The Radiopharmaceutical Revolution: New Frontiers in Prostate Cancer Treatment
|
A. Oliver Sartor, MD
Oliver Sartor discusses the rapidly evolving landscape of radiopharmaceuticals for prostate cancer with Alicia Morgans. Dr. Sartor highlights significant advances, such as the VISION trial, which targets late-stage patients, and the PSMAfore trial which focuses on pre-chemo patients.
|
|
|
|
|
|
|
|
|
|
|
|
Expanding the Nuclear Hot Lab to Accommodate Lutetium-177
|
Lyanne Gomez
Phillip Koo tours the "hot lab" at an infusion center, guided by Lyanne Gomez, a nuclear medicine technologist. The conversation provides an in-depth look at the equipment used for handling lutetium Lu 177 vipivotide tetraxetan (PLUVICTO®).
|
|
|
|
|
|
|
|
|
|
|
|
Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors
|
Rana McKay, MD
Alicia Morgans and Rana McKay delve into the complexities of treatment sequencing for metastatic castration-resistant prostate cancer. They highlight the expansive range of available therapies, including hormonal, targeted, immunotherapies, chemotherapy, and radioligand therapies.
|
|
|
|
|
|
|
|
|
|
|
| PSMA Radioligands: Current and Future
|
| Scott T. Tagawa, MD, MS, FACP, FASCO
|
| Scott Tagawa discusses the current status and future applications of targeted radionuclides, focusing on PSMA-targeted radionuclide therapy for mCRPC. He outlines various PSMA-targeted radionuclide therapeutics, such as 177Lu-PSMA-617, 177Lu-PSMA I&T, and 177Lu-J591, highlighting trials like TheraP and VISION.
|
|
|
|
|
|
| Burning Questions in Oncological Urology: The Current and Future Role of PSMA-Based Theranostics in Men with Advanced Prostate Cancer
|
| Silke Gillessen Sommer, MD
|
| Professor Silke Gillessen Sommer discusses the current and future role of PSMA-based theranostics in men with advanced prostate cancer. She highlights the VISION trial, which evaluated 177Lu-PSMA-617 in men with PSMA-positive metastatic castrate-resistant prostate cancer, showing a significant improvement in overall survival.
|
|
|
|
|
|
|
|
|
|
|
| Metastatic Prostate Cancer: Possible Synergies Between Radioligand and Systemic Treatment in M1 Prostate Cancer? Future Perspectives
|
| Ken Herrmann, MD, MBA
|
| Ken Herrmann discusses future perspectives for possible synergies between radioligand and systemic treatment in metastatic prostate cancer. He emphasizes the importance of aiming for synergism, citing the VISION trial where a significant percentage of patients showed a substantial decrease in disease.
|
|
|
|
|
|
| Observations on the Biology of PSMA Implications for Targeting
|
| Neil Bander, MD
|
| Neil Bander presents on the biology of PSMA and its implications for targeting. He discusses the inverse regulation of PSMA by the androgen receptor, highlighting that anti-androgen therapies have significant effects on PSMA expression, taking about 2 weeks to reach peak levels.
|
|
|
|
|
|
| Looking Ahead: Novel Agents in Castration-Resistant Prostate Cancer
|
| Pedro Barata, MD, MSc
|
| Pedro Barata discusses two abstracts focusing on novel therapeutic approaches for castration-resistant prostate cancer. The first abstract highlighted the progress and challenges in PSMA-based radioligand therapy, emphasizing the potential of combining alpha and beta emitters for improved efficacy. The second abstract discussed the use of PSCA-targeted CAR-T cells, noting safety concerns and the need for further research to harness the promising anti-cancer effects of this emerging therapy.
|
|
|
|
|
|
|
